Chronic liver disease and cirrhosis are growing global problems which can alter the pharmacokinetics and pharmacodynamics of medications. Underlying liver disease increases the susceptibility to drug-induced liver injury in certain contexts and patients with cirrhosis that experience hepatotoxicity may have worse outcomes. Yet the existing data are somewhat conflicting. In this presentation, the speaker will review the existing literature related to the potential mechanisms for increased drug hepatotoxicity in patients with chronic liver diseases such as MASLD and cirrhosis. Further, the speaker will discuss the controversies in this topic, current knowledge gaps, and suggest areas for future research to improve our understanding of this critically important problem.

This activity was originally presented on February 8, 2025.

COPYRIGHT:  All faculty in this activity have given their permission for publication ©2024 AASLD.

This activity will not offer CE Credit.

Naga Chalasani, MD, FAASLD

PRIVACY POLICY: https://www.aasld.org/terms-use-and-privacy-policy